Global NK-1 Receptor Antagonists Market Growth 2026-2032
The global NK-1 Receptor Antagonists market size is predicted to grow from US$ 834 million in 2025 to US$ 1333 million in 2032; it is expected to grow at a CAGR of 7.1% from 2026 to 2032.
NK-1 receptor antagonists are a class of drugs that block the neurokinin-1 (NK1) receptors, which are activated by the neurotransmitter substance P. Substance P plays a key role in the body's vomiting reflex, as well as in pain perception and stress responses. By inhibiting NK1 receptors, these drugs are primarily used to prevent and treat nausea and vomiting, particularly those caused by chemotherapy, radiation therapy, or surgery. In 2024, the global sales volume of NK-1 receptor antagonists reached 3.65 million units, with an average price of 220 USD per unit.
Regional Market Landscape
NK-1 receptor antagonists exhibit a distinct regional distribution in the global market. North America accounts for 45% of the total market, driven primarily by the mature pharmaceutical R&D infrastructure and high treatment demand in the United States. Europe follows with a 28% share, led by Germany, France, and the United Kingdom, where healthcare insurance coverage and acceptance of innovative drugs are high. The Asia-Pacific region holds 20% of the market, with China, Japan, and India as core contributors, reflecting steady growth in demand due to the increasing prevalence of chronic diseases and cancer. Latin America and the Middle East & Africa together represent 7%, primarily supported by Brazil, Mexico, and South Africa, where market development is relatively slower due to limited healthcare coverage but potential for growth exists.
Key Manufacturers and Industry Competition
The NK-1 receptor antagonist industry demonstrates an oligopolistic competitive structure. Major manufacturers include global companies such as Merck, Glenmark, and Sandoz, alongside regional players like Fosun Pharma and Hengrui Medicine in China. Upstream, these companies rely on raw material suppliers such as Lonza and WuXi AppTec, while downstream distribution channels include hospitals, pharmacy chains, and specialized medical institutions. Competition extends beyond pricing and sales networks, focusing also on R&D pipelines and expansion into new indications. Strategic partnerships, mergers, and licensing agreements are employed to integrate the supply chain, enhance market share, and strengthen technological barriers.
Technology Trends and Innovation Directions
Technological development in NK-1 receptor antagonists focuses on improving drug selectivity, prolonging half-life, and enhancing oral bioavailability. Molecular design and structural optimization are central to R&D, leveraging high-throughput screening and computer-aided drug design to increase target affinity and specificity. Innovation in delivery systems, including nanoparticle carriers and long-acting formulations, aims to improve patient adherence. Future innovations also involve combination therapies with other mechanisms and the development of personalized medicine approaches to meet the needs of diverse patient populations.
Policy and Industry Development Drivers
Healthcare policies and regulatory frameworks play a key role in the development of the NK-1 receptor antagonist market worldwide. The United States and Europe maintain strict but transparent approval systems that accelerate the launch of innovative drugs, while China encourages R&D through policies supporting innovation and generic consistency evaluation. Reimbursement policies and patient affordability directly affect market penetration, while updates to clinical guidelines and health management programs indirectly expand demand. Policy support and industry standardization drive higher market concentration and accelerate technological innovation.
Future Outlook
With the global increase in chronic disease and cancer patient populations, the NK-1 receptor antagonist market is expected to maintain steady long-term growth. Technological innovation will enhance drug efficacy, improve patient adherence, and reduce side effects and treatment costs. Integration of the supply chain and international expansion will strengthen corporate competitiveness, and regional market differentiation strategies will become a focus for development. Overall, the industry outlook is positive, with the next decade likely to be dominated by high-value innovative drugs alongside cross-border collaboration and regional market expansion.
LP Information, Inc. (LPI) ' newest research report, the “NK-1 Receptor Antagonists Industry Forecast” looks at past sales and reviews total world NK-1 Receptor Antagonists sales in 2025, providing a comprehensive analysis by region and market sector of projected NK-1 Receptor Antagonists sales for 2026 through 2032. With NK-1 Receptor Antagonists sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world NK-1 Receptor Antagonists industry.
This Insight Report provides a comprehensive analysis of the global NK-1 Receptor Antagonists landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on NK-1 Receptor Antagonists portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global NK-1 Receptor Antagonists market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for NK-1 Receptor Antagonists and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global NK-1 Receptor Antagonists.
This report presents a comprehensive overview, market shares, and growth opportunities of NK-1 Receptor Antagonists market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
What is the 10-year outlook for the global NK-1 Receptor Antagonists market?
What factors are driving NK-1 Receptor Antagonists market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do NK-1 Receptor Antagonists market opportunities vary by end market size?
How does NK-1 Receptor Antagonists break out by Type, by Application?
The report requires updating with new data and is sent in 48 hours after order is placed.
NK-1 receptor antagonists are a class of drugs that block the neurokinin-1 (NK1) receptors, which are activated by the neurotransmitter substance P. Substance P plays a key role in the body's vomiting reflex, as well as in pain perception and stress responses. By inhibiting NK1 receptors, these drugs are primarily used to prevent and treat nausea and vomiting, particularly those caused by chemotherapy, radiation therapy, or surgery. In 2024, the global sales volume of NK-1 receptor antagonists reached 3.65 million units, with an average price of 220 USD per unit.
Regional Market Landscape
NK-1 receptor antagonists exhibit a distinct regional distribution in the global market. North America accounts for 45% of the total market, driven primarily by the mature pharmaceutical R&D infrastructure and high treatment demand in the United States. Europe follows with a 28% share, led by Germany, France, and the United Kingdom, where healthcare insurance coverage and acceptance of innovative drugs are high. The Asia-Pacific region holds 20% of the market, with China, Japan, and India as core contributors, reflecting steady growth in demand due to the increasing prevalence of chronic diseases and cancer. Latin America and the Middle East & Africa together represent 7%, primarily supported by Brazil, Mexico, and South Africa, where market development is relatively slower due to limited healthcare coverage but potential for growth exists.
Key Manufacturers and Industry Competition
The NK-1 receptor antagonist industry demonstrates an oligopolistic competitive structure. Major manufacturers include global companies such as Merck, Glenmark, and Sandoz, alongside regional players like Fosun Pharma and Hengrui Medicine in China. Upstream, these companies rely on raw material suppliers such as Lonza and WuXi AppTec, while downstream distribution channels include hospitals, pharmacy chains, and specialized medical institutions. Competition extends beyond pricing and sales networks, focusing also on R&D pipelines and expansion into new indications. Strategic partnerships, mergers, and licensing agreements are employed to integrate the supply chain, enhance market share, and strengthen technological barriers.
Technology Trends and Innovation Directions
Technological development in NK-1 receptor antagonists focuses on improving drug selectivity, prolonging half-life, and enhancing oral bioavailability. Molecular design and structural optimization are central to R&D, leveraging high-throughput screening and computer-aided drug design to increase target affinity and specificity. Innovation in delivery systems, including nanoparticle carriers and long-acting formulations, aims to improve patient adherence. Future innovations also involve combination therapies with other mechanisms and the development of personalized medicine approaches to meet the needs of diverse patient populations.
Policy and Industry Development Drivers
Healthcare policies and regulatory frameworks play a key role in the development of the NK-1 receptor antagonist market worldwide. The United States and Europe maintain strict but transparent approval systems that accelerate the launch of innovative drugs, while China encourages R&D through policies supporting innovation and generic consistency evaluation. Reimbursement policies and patient affordability directly affect market penetration, while updates to clinical guidelines and health management programs indirectly expand demand. Policy support and industry standardization drive higher market concentration and accelerate technological innovation.
Future Outlook
With the global increase in chronic disease and cancer patient populations, the NK-1 receptor antagonist market is expected to maintain steady long-term growth. Technological innovation will enhance drug efficacy, improve patient adherence, and reduce side effects and treatment costs. Integration of the supply chain and international expansion will strengthen corporate competitiveness, and regional market differentiation strategies will become a focus for development. Overall, the industry outlook is positive, with the next decade likely to be dominated by high-value innovative drugs alongside cross-border collaboration and regional market expansion.
LP Information, Inc. (LPI) ' newest research report, the “NK-1 Receptor Antagonists Industry Forecast” looks at past sales and reviews total world NK-1 Receptor Antagonists sales in 2025, providing a comprehensive analysis by region and market sector of projected NK-1 Receptor Antagonists sales for 2026 through 2032. With NK-1 Receptor Antagonists sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world NK-1 Receptor Antagonists industry.
This Insight Report provides a comprehensive analysis of the global NK-1 Receptor Antagonists landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on NK-1 Receptor Antagonists portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global NK-1 Receptor Antagonists market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for NK-1 Receptor Antagonists and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global NK-1 Receptor Antagonists.
This report presents a comprehensive overview, market shares, and growth opportunities of NK-1 Receptor Antagonists market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
- Aprepitant
- Rolapitant
- Fosaprepitant
- Netupitant
- Maropitant
- Other
- Chemotherapy-induced Nausea and Vomiting (CINV)
- Postoperative Nausea and Vomiting (PONV)
- Other
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- Merck
- TerSera Therapeutics
- Helsinn Healthcare
- Heron Therapeutics
- Sandoz
- Glenmark
- Torrent Pharmaceuticals
- Steriscience
- Mylan
- Fresenius
- MSN
- Teva
- Eugia Pharma
- Lupin
- Dr. Reddy's Laboratories
- Chia Tai Tianqing Pharmaceutical
- Qilu Pharmaceutical
- Beijing Sihuan Pharmaceutical
- Yichang Humanwell Pharmaceutical
- Hansoh Pharma
What is the 10-year outlook for the global NK-1 Receptor Antagonists market?
What factors are driving NK-1 Receptor Antagonists market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do NK-1 Receptor Antagonists market opportunities vary by end market size?
How does NK-1 Receptor Antagonists break out by Type, by Application?
The report requires updating with new data and is sent in 48 hours after order is placed.
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global NK-1 Receptor Antagonists Annual Sales 2021-2032
2.1.2 World Current & Future Analysis for NK-1 Receptor Antagonists by Geographic Region, 2021, 2025 & 2032
2.1.3 World Current & Future Analysis for NK-1 Receptor Antagonists by Country/Region, 2021, 2025 & 2032
2.2 NK-1 Receptor Antagonists Segment by Type
2.2.1 Aprepitant
2.2.2 Rolapitant
2.2.3 Fosaprepitant
2.2.4 Netupitant
2.2.5 Maropitant
2.2.6 Other
2.2.7 NK-1 Receptor Antagonists Sales by Type
2.2.7.1 Global NK-1 Receptor Antagonists Sales Market Share by Type (2021-2026)
2.2.7.2 Global NK-1 Receptor Antagonists Revenue and Market Share by Type (2021-2026)
2.2.7.3 Global NK-1 Receptor Antagonists Sale Price by Type (2021-2026)
2.3 NK-1 Receptor Antagonists Segment by Application
2.3.1 Chemotherapy-induced Nausea and Vomiting (CINV)
2.3.2 Postoperative Nausea and Vomiting (PONV)
2.3.3 Other
2.3.4 NK-1 Receptor Antagonists Sales by Application
2.3.4.1 Global NK-1 Receptor Antagonists Sale Market Share by Application (2021-2026)
2.3.4.2 Global NK-1 Receptor Antagonists Revenue and Market Share by Application (2021-2026)
2.3.4.3 Global NK-1 Receptor Antagonists Sale Price by Application (2021-2026)
3 GLOBAL BY COMPANY
3.1 Global NK-1 Receptor Antagonists Breakdown Data by Company
3.1.1 Global NK-1 Receptor Antagonists Annual Sales by Company (2021-2026)
3.1.2 Global NK-1 Receptor Antagonists Sales Market Share by Company (2021-2026)
3.2 Global NK-1 Receptor Antagonists Annual Revenue by Company (2021-2026)
3.2.1 Global NK-1 Receptor Antagonists Revenue by Company (2021-2026)
3.2.2 Global NK-1 Receptor Antagonists Revenue Market Share by Company (2021-2026)
3.3 Global NK-1 Receptor Antagonists Sale Price by Company
3.4 Key Manufacturers NK-1 Receptor Antagonists Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers NK-1 Receptor Antagonists Product Location Distribution
3.4.2 Players NK-1 Receptor Antagonists Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR NK-1 RECEPTOR ANTAGONISTS BY GEOGRAPHIC REGION
4.1 World Historic NK-1 Receptor Antagonists Market Size by Geographic Region (2021-2026)
4.1.1 Global NK-1 Receptor Antagonists Annual Sales by Geographic Region (2021-2026)
4.1.2 Global NK-1 Receptor Antagonists Annual Revenue by Geographic Region (2021-2026)
4.2 World Historic NK-1 Receptor Antagonists Market Size by Country/Region (2021-2026)
4.2.1 Global NK-1 Receptor Antagonists Annual Sales by Country/Region (2021-2026)
4.2.2 Global NK-1 Receptor Antagonists Annual Revenue by Country/Region (2021-2026)
4.3 Americas NK-1 Receptor Antagonists Sales Growth
4.4 APAC NK-1 Receptor Antagonists Sales Growth
4.5 Europe NK-1 Receptor Antagonists Sales Growth
4.6 Middle East & Africa NK-1 Receptor Antagonists Sales Growth
5 AMERICAS
5.1 Americas NK-1 Receptor Antagonists Sales by Country
5.1.1 Americas NK-1 Receptor Antagonists Sales by Country (2021-2026)
5.1.2 Americas NK-1 Receptor Antagonists Revenue by Country (2021-2026)
5.2 Americas NK-1 Receptor Antagonists Sales by Type (2021-2026)
5.3 Americas NK-1 Receptor Antagonists Sales by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC NK-1 Receptor Antagonists Sales by Region
6.1.1 APAC NK-1 Receptor Antagonists Sales by Region (2021-2026)
6.1.2 APAC NK-1 Receptor Antagonists Revenue by Region (2021-2026)
6.2 APAC NK-1 Receptor Antagonists Sales by Type (2021-2026)
6.3 APAC NK-1 Receptor Antagonists Sales by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe NK-1 Receptor Antagonists by Country
7.1.1 Europe NK-1 Receptor Antagonists Sales by Country (2021-2026)
7.1.2 Europe NK-1 Receptor Antagonists Revenue by Country (2021-2026)
7.2 Europe NK-1 Receptor Antagonists Sales by Type (2021-2026)
7.3 Europe NK-1 Receptor Antagonists Sales by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa NK-1 Receptor Antagonists by Country
8.1.1 Middle East & Africa NK-1 Receptor Antagonists Sales by Country (2021-2026)
8.1.2 Middle East & Africa NK-1 Receptor Antagonists Revenue by Country (2021-2026)
8.2 Middle East & Africa NK-1 Receptor Antagonists Sales by Type (2021-2026)
8.3 Middle East & Africa NK-1 Receptor Antagonists Sales by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of NK-1 Receptor Antagonists
10.3 Manufacturing Process Analysis of NK-1 Receptor Antagonists
10.4 Industry Chain Structure of NK-1 Receptor Antagonists
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 NK-1 Receptor Antagonists Distributors
11.3 NK-1 Receptor Antagonists Customer
12 WORLD FORECAST REVIEW FOR NK-1 RECEPTOR ANTAGONISTS BY GEOGRAPHIC REGION
12.1 Global NK-1 Receptor Antagonists Market Size Forecast by Region
12.1.1 Global NK-1 Receptor Antagonists Forecast by Region (2027-2032)
12.1.2 Global NK-1 Receptor Antagonists Annual Revenue Forecast by Region (2027-2032)
12.2 Americas Forecast by Country (2027-2032)
12.3 APAC Forecast by Region (2027-2032)
12.4 Europe Forecast by Country (2027-2032)
12.5 Middle East & Africa Forecast by Country (2027-2032)
12.6 Global NK-1 Receptor Antagonists Forecast by Type (2027-2032)
12.7 Global NK-1 Receptor Antagonists Forecast by Application (2027-2032)
13 KEY PLAYERS ANALYSIS
13.1 Merck
13.1.1 Merck Company Information
13.1.2 Merck NK-1 Receptor Antagonists Product Portfolios and Specifications
13.1.3 Merck NK-1 Receptor Antagonists Sales, Revenue, Price and Gross Margin (2021-2026)
13.1.4 Merck Main Business Overview
13.1.5 Merck Latest Developments
13.2 TerSera Therapeutics
13.2.1 TerSera Therapeutics Company Information
13.2.2 TerSera Therapeutics NK-1 Receptor Antagonists Product Portfolios and Specifications
13.2.3 TerSera Therapeutics NK-1 Receptor Antagonists Sales, Revenue, Price and Gross Margin (2021-2026)
13.2.4 TerSera Therapeutics Main Business Overview
13.2.5 TerSera Therapeutics Latest Developments
13.3 Helsinn Healthcare
13.3.1 Helsinn Healthcare Company Information
13.3.2 Helsinn Healthcare NK-1 Receptor Antagonists Product Portfolios and Specifications
13.3.3 Helsinn Healthcare NK-1 Receptor Antagonists Sales, Revenue, Price and Gross Margin (2021-2026)
13.3.4 Helsinn Healthcare Main Business Overview
13.3.5 Helsinn Healthcare Latest Developments
13.4 Heron Therapeutics
13.4.1 Heron Therapeutics Company Information
13.4.2 Heron Therapeutics NK-1 Receptor Antagonists Product Portfolios and Specifications
13.4.3 Heron Therapeutics NK-1 Receptor Antagonists Sales, Revenue, Price and Gross Margin (2021-2026)
13.4.4 Heron Therapeutics Main Business Overview
13.4.5 Heron Therapeutics Latest Developments
13.5 Sandoz
13.5.1 Sandoz Company Information
13.5.2 Sandoz NK-1 Receptor Antagonists Product Portfolios and Specifications
13.5.3 Sandoz NK-1 Receptor Antagonists Sales, Revenue, Price and Gross Margin (2021-2026)
13.5.4 Sandoz Main Business Overview
13.5.5 Sandoz Latest Developments
13.6 Glenmark
13.6.1 Glenmark Company Information
13.6.2 Glenmark NK-1 Receptor Antagonists Product Portfolios and Specifications
13.6.3 Glenmark NK-1 Receptor Antagonists Sales, Revenue, Price and Gross Margin (2021-2026)
13.6.4 Glenmark Main Business Overview
13.6.5 Glenmark Latest Developments
13.7 Torrent Pharmaceuticals
13.7.1 Torrent Pharmaceuticals Company Information
13.7.2 Torrent Pharmaceuticals NK-1 Receptor Antagonists Product Portfolios and Specifications
13.7.3 Torrent Pharmaceuticals NK-1 Receptor Antagonists Sales, Revenue, Price and Gross Margin (2021-2026)
13.7.4 Torrent Pharmaceuticals Main Business Overview
13.7.5 Torrent Pharmaceuticals Latest Developments
13.8 Steriscience
13.8.1 Steriscience Company Information
13.8.2 Steriscience NK-1 Receptor Antagonists Product Portfolios and Specifications
13.8.3 Steriscience NK-1 Receptor Antagonists Sales, Revenue, Price and Gross Margin (2021-2026)
13.8.4 Steriscience Main Business Overview
13.8.5 Steriscience Latest Developments
13.9 Mylan
13.9.1 Mylan Company Information
13.9.2 Mylan NK-1 Receptor Antagonists Product Portfolios and Specifications
13.9.3 Mylan NK-1 Receptor Antagonists Sales, Revenue, Price and Gross Margin (2021-2026)
13.9.4 Mylan Main Business Overview
13.9.5 Mylan Latest Developments
13.10 Fresenius
13.10.1 Fresenius Company Information
13.10.2 Fresenius NK-1 Receptor Antagonists Product Portfolios and Specifications
13.10.3 Fresenius NK-1 Receptor Antagonists Sales, Revenue, Price and Gross Margin (2021-2026)
13.10.4 Fresenius Main Business Overview
13.10.5 Fresenius Latest Developments
13.11 MSN
13.11.1 MSN Company Information
13.11.2 MSN NK-1 Receptor Antagonists Product Portfolios and Specifications
13.11.3 MSN NK-1 Receptor Antagonists Sales, Revenue, Price and Gross Margin (2021-2026)
13.11.4 MSN Main Business Overview
13.11.5 MSN Latest Developments
13.12 Teva
13.12.1 Teva Company Information
13.12.2 Teva NK-1 Receptor Antagonists Product Portfolios and Specifications
13.12.3 Teva NK-1 Receptor Antagonists Sales, Revenue, Price and Gross Margin (2021-2026)
13.12.4 Teva Main Business Overview
13.12.5 Teva Latest Developments
13.13 Eugia Pharma
13.13.1 Eugia Pharma Company Information
13.13.2 Eugia Pharma NK-1 Receptor Antagonists Product Portfolios and Specifications
13.13.3 Eugia Pharma NK-1 Receptor Antagonists Sales, Revenue, Price and Gross Margin (2021-2026)
13.13.4 Eugia Pharma Main Business Overview
13.13.5 Eugia Pharma Latest Developments
13.14 Lupin
13.14.1 Lupin Company Information
13.14.2 Lupin NK-1 Receptor Antagonists Product Portfolios and Specifications
13.14.3 Lupin NK-1 Receptor Antagonists Sales, Revenue, Price and Gross Margin (2021-2026)
13.14.4 Lupin Main Business Overview
13.14.5 Lupin Latest Developments
13.15 Dr. Reddy's Laboratories
13.15.1 Dr. Reddy's Laboratories Company Information
13.15.2 Dr. Reddy's Laboratories NK-1 Receptor Antagonists Product Portfolios and Specifications
13.15.3 Dr. Reddy's Laboratories NK-1 Receptor Antagonists Sales, Revenue, Price and Gross Margin (2021-2026)
13.15.4 Dr. Reddy's Laboratories Main Business Overview
13.15.5 Dr. Reddy's Laboratories Latest Developments
13.16 Chia Tai Tianqing Pharmaceutical
13.16.1 Chia Tai Tianqing Pharmaceutical Company Information
13.16.2 Chia Tai Tianqing Pharmaceutical NK-1 Receptor Antagonists Product Portfolios and Specifications
13.16.3 Chia Tai Tianqing Pharmaceutical NK-1 Receptor Antagonists Sales, Revenue, Price and Gross Margin (2021-2026)
13.16.4 Chia Tai Tianqing Pharmaceutical Main Business Overview
13.16.5 Chia Tai Tianqing Pharmaceutical Latest Developments
13.17 Qilu Pharmaceutical
13.17.1 Qilu Pharmaceutical Company Information
13.17.2 Qilu Pharmaceutical NK-1 Receptor Antagonists Product Portfolios and Specifications
13.17.3 Qilu Pharmaceutical NK-1 Receptor Antagonists Sales, Revenue, Price and Gross Margin (2021-2026)
13.17.4 Qilu Pharmaceutical Main Business Overview
13.17.5 Qilu Pharmaceutical Latest Developments
13.18 Beijing Sihuan Pharmaceutical
13.18.1 Beijing Sihuan Pharmaceutical Company Information
13.18.2 Beijing Sihuan Pharmaceutical NK-1 Receptor Antagonists Product Portfolios and Specifications
13.18.3 Beijing Sihuan Pharmaceutical NK-1 Receptor Antagonists Sales, Revenue, Price and Gross Margin (2021-2026)
13.18.4 Beijing Sihuan Pharmaceutical Main Business Overview
13.18.5 Beijing Sihuan Pharmaceutical Latest Developments
13.19 Yichang Humanwell Pharmaceutical
13.19.1 Yichang Humanwell Pharmaceutical Company Information
13.19.2 Yichang Humanwell Pharmaceutical NK-1 Receptor Antagonists Product Portfolios and Specifications
13.19.3 Yichang Humanwell Pharmaceutical NK-1 Receptor Antagonists Sales, Revenue, Price and Gross Margin (2021-2026)
13.19.4 Yichang Humanwell Pharmaceutical Main Business Overview
13.19.5 Yichang Humanwell Pharmaceutical Latest Developments
13.20 Hansoh Pharma
13.20.1 Hansoh Pharma Company Information
13.20.2 Hansoh Pharma NK-1 Receptor Antagonists Product Portfolios and Specifications
13.20.3 Hansoh Pharma NK-1 Receptor Antagonists Sales, Revenue, Price and Gross Margin (2021-2026)
13.20.4 Hansoh Pharma Main Business Overview
13.20.5 Hansoh Pharma Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global NK-1 Receptor Antagonists Annual Sales 2021-2032
2.1.2 World Current & Future Analysis for NK-1 Receptor Antagonists by Geographic Region, 2021, 2025 & 2032
2.1.3 World Current & Future Analysis for NK-1 Receptor Antagonists by Country/Region, 2021, 2025 & 2032
2.2 NK-1 Receptor Antagonists Segment by Type
2.2.1 Aprepitant
2.2.2 Rolapitant
2.2.3 Fosaprepitant
2.2.4 Netupitant
2.2.5 Maropitant
2.2.6 Other
2.2.7 NK-1 Receptor Antagonists Sales by Type
2.2.7.1 Global NK-1 Receptor Antagonists Sales Market Share by Type (2021-2026)
2.2.7.2 Global NK-1 Receptor Antagonists Revenue and Market Share by Type (2021-2026)
2.2.7.3 Global NK-1 Receptor Antagonists Sale Price by Type (2021-2026)
2.3 NK-1 Receptor Antagonists Segment by Application
2.3.1 Chemotherapy-induced Nausea and Vomiting (CINV)
2.3.2 Postoperative Nausea and Vomiting (PONV)
2.3.3 Other
2.3.4 NK-1 Receptor Antagonists Sales by Application
2.3.4.1 Global NK-1 Receptor Antagonists Sale Market Share by Application (2021-2026)
2.3.4.2 Global NK-1 Receptor Antagonists Revenue and Market Share by Application (2021-2026)
2.3.4.3 Global NK-1 Receptor Antagonists Sale Price by Application (2021-2026)
3 GLOBAL BY COMPANY
3.1 Global NK-1 Receptor Antagonists Breakdown Data by Company
3.1.1 Global NK-1 Receptor Antagonists Annual Sales by Company (2021-2026)
3.1.2 Global NK-1 Receptor Antagonists Sales Market Share by Company (2021-2026)
3.2 Global NK-1 Receptor Antagonists Annual Revenue by Company (2021-2026)
3.2.1 Global NK-1 Receptor Antagonists Revenue by Company (2021-2026)
3.2.2 Global NK-1 Receptor Antagonists Revenue Market Share by Company (2021-2026)
3.3 Global NK-1 Receptor Antagonists Sale Price by Company
3.4 Key Manufacturers NK-1 Receptor Antagonists Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers NK-1 Receptor Antagonists Product Location Distribution
3.4.2 Players NK-1 Receptor Antagonists Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR NK-1 RECEPTOR ANTAGONISTS BY GEOGRAPHIC REGION
4.1 World Historic NK-1 Receptor Antagonists Market Size by Geographic Region (2021-2026)
4.1.1 Global NK-1 Receptor Antagonists Annual Sales by Geographic Region (2021-2026)
4.1.2 Global NK-1 Receptor Antagonists Annual Revenue by Geographic Region (2021-2026)
4.2 World Historic NK-1 Receptor Antagonists Market Size by Country/Region (2021-2026)
4.2.1 Global NK-1 Receptor Antagonists Annual Sales by Country/Region (2021-2026)
4.2.2 Global NK-1 Receptor Antagonists Annual Revenue by Country/Region (2021-2026)
4.3 Americas NK-1 Receptor Antagonists Sales Growth
4.4 APAC NK-1 Receptor Antagonists Sales Growth
4.5 Europe NK-1 Receptor Antagonists Sales Growth
4.6 Middle East & Africa NK-1 Receptor Antagonists Sales Growth
5 AMERICAS
5.1 Americas NK-1 Receptor Antagonists Sales by Country
5.1.1 Americas NK-1 Receptor Antagonists Sales by Country (2021-2026)
5.1.2 Americas NK-1 Receptor Antagonists Revenue by Country (2021-2026)
5.2 Americas NK-1 Receptor Antagonists Sales by Type (2021-2026)
5.3 Americas NK-1 Receptor Antagonists Sales by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC NK-1 Receptor Antagonists Sales by Region
6.1.1 APAC NK-1 Receptor Antagonists Sales by Region (2021-2026)
6.1.2 APAC NK-1 Receptor Antagonists Revenue by Region (2021-2026)
6.2 APAC NK-1 Receptor Antagonists Sales by Type (2021-2026)
6.3 APAC NK-1 Receptor Antagonists Sales by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe NK-1 Receptor Antagonists by Country
7.1.1 Europe NK-1 Receptor Antagonists Sales by Country (2021-2026)
7.1.2 Europe NK-1 Receptor Antagonists Revenue by Country (2021-2026)
7.2 Europe NK-1 Receptor Antagonists Sales by Type (2021-2026)
7.3 Europe NK-1 Receptor Antagonists Sales by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa NK-1 Receptor Antagonists by Country
8.1.1 Middle East & Africa NK-1 Receptor Antagonists Sales by Country (2021-2026)
8.1.2 Middle East & Africa NK-1 Receptor Antagonists Revenue by Country (2021-2026)
8.2 Middle East & Africa NK-1 Receptor Antagonists Sales by Type (2021-2026)
8.3 Middle East & Africa NK-1 Receptor Antagonists Sales by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of NK-1 Receptor Antagonists
10.3 Manufacturing Process Analysis of NK-1 Receptor Antagonists
10.4 Industry Chain Structure of NK-1 Receptor Antagonists
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 NK-1 Receptor Antagonists Distributors
11.3 NK-1 Receptor Antagonists Customer
12 WORLD FORECAST REVIEW FOR NK-1 RECEPTOR ANTAGONISTS BY GEOGRAPHIC REGION
12.1 Global NK-1 Receptor Antagonists Market Size Forecast by Region
12.1.1 Global NK-1 Receptor Antagonists Forecast by Region (2027-2032)
12.1.2 Global NK-1 Receptor Antagonists Annual Revenue Forecast by Region (2027-2032)
12.2 Americas Forecast by Country (2027-2032)
12.3 APAC Forecast by Region (2027-2032)
12.4 Europe Forecast by Country (2027-2032)
12.5 Middle East & Africa Forecast by Country (2027-2032)
12.6 Global NK-1 Receptor Antagonists Forecast by Type (2027-2032)
12.7 Global NK-1 Receptor Antagonists Forecast by Application (2027-2032)
13 KEY PLAYERS ANALYSIS
13.1 Merck
13.1.1 Merck Company Information
13.1.2 Merck NK-1 Receptor Antagonists Product Portfolios and Specifications
13.1.3 Merck NK-1 Receptor Antagonists Sales, Revenue, Price and Gross Margin (2021-2026)
13.1.4 Merck Main Business Overview
13.1.5 Merck Latest Developments
13.2 TerSera Therapeutics
13.2.1 TerSera Therapeutics Company Information
13.2.2 TerSera Therapeutics NK-1 Receptor Antagonists Product Portfolios and Specifications
13.2.3 TerSera Therapeutics NK-1 Receptor Antagonists Sales, Revenue, Price and Gross Margin (2021-2026)
13.2.4 TerSera Therapeutics Main Business Overview
13.2.5 TerSera Therapeutics Latest Developments
13.3 Helsinn Healthcare
13.3.1 Helsinn Healthcare Company Information
13.3.2 Helsinn Healthcare NK-1 Receptor Antagonists Product Portfolios and Specifications
13.3.3 Helsinn Healthcare NK-1 Receptor Antagonists Sales, Revenue, Price and Gross Margin (2021-2026)
13.3.4 Helsinn Healthcare Main Business Overview
13.3.5 Helsinn Healthcare Latest Developments
13.4 Heron Therapeutics
13.4.1 Heron Therapeutics Company Information
13.4.2 Heron Therapeutics NK-1 Receptor Antagonists Product Portfolios and Specifications
13.4.3 Heron Therapeutics NK-1 Receptor Antagonists Sales, Revenue, Price and Gross Margin (2021-2026)
13.4.4 Heron Therapeutics Main Business Overview
13.4.5 Heron Therapeutics Latest Developments
13.5 Sandoz
13.5.1 Sandoz Company Information
13.5.2 Sandoz NK-1 Receptor Antagonists Product Portfolios and Specifications
13.5.3 Sandoz NK-1 Receptor Antagonists Sales, Revenue, Price and Gross Margin (2021-2026)
13.5.4 Sandoz Main Business Overview
13.5.5 Sandoz Latest Developments
13.6 Glenmark
13.6.1 Glenmark Company Information
13.6.2 Glenmark NK-1 Receptor Antagonists Product Portfolios and Specifications
13.6.3 Glenmark NK-1 Receptor Antagonists Sales, Revenue, Price and Gross Margin (2021-2026)
13.6.4 Glenmark Main Business Overview
13.6.5 Glenmark Latest Developments
13.7 Torrent Pharmaceuticals
13.7.1 Torrent Pharmaceuticals Company Information
13.7.2 Torrent Pharmaceuticals NK-1 Receptor Antagonists Product Portfolios and Specifications
13.7.3 Torrent Pharmaceuticals NK-1 Receptor Antagonists Sales, Revenue, Price and Gross Margin (2021-2026)
13.7.4 Torrent Pharmaceuticals Main Business Overview
13.7.5 Torrent Pharmaceuticals Latest Developments
13.8 Steriscience
13.8.1 Steriscience Company Information
13.8.2 Steriscience NK-1 Receptor Antagonists Product Portfolios and Specifications
13.8.3 Steriscience NK-1 Receptor Antagonists Sales, Revenue, Price and Gross Margin (2021-2026)
13.8.4 Steriscience Main Business Overview
13.8.5 Steriscience Latest Developments
13.9 Mylan
13.9.1 Mylan Company Information
13.9.2 Mylan NK-1 Receptor Antagonists Product Portfolios and Specifications
13.9.3 Mylan NK-1 Receptor Antagonists Sales, Revenue, Price and Gross Margin (2021-2026)
13.9.4 Mylan Main Business Overview
13.9.5 Mylan Latest Developments
13.10 Fresenius
13.10.1 Fresenius Company Information
13.10.2 Fresenius NK-1 Receptor Antagonists Product Portfolios and Specifications
13.10.3 Fresenius NK-1 Receptor Antagonists Sales, Revenue, Price and Gross Margin (2021-2026)
13.10.4 Fresenius Main Business Overview
13.10.5 Fresenius Latest Developments
13.11 MSN
13.11.1 MSN Company Information
13.11.2 MSN NK-1 Receptor Antagonists Product Portfolios and Specifications
13.11.3 MSN NK-1 Receptor Antagonists Sales, Revenue, Price and Gross Margin (2021-2026)
13.11.4 MSN Main Business Overview
13.11.5 MSN Latest Developments
13.12 Teva
13.12.1 Teva Company Information
13.12.2 Teva NK-1 Receptor Antagonists Product Portfolios and Specifications
13.12.3 Teva NK-1 Receptor Antagonists Sales, Revenue, Price and Gross Margin (2021-2026)
13.12.4 Teva Main Business Overview
13.12.5 Teva Latest Developments
13.13 Eugia Pharma
13.13.1 Eugia Pharma Company Information
13.13.2 Eugia Pharma NK-1 Receptor Antagonists Product Portfolios and Specifications
13.13.3 Eugia Pharma NK-1 Receptor Antagonists Sales, Revenue, Price and Gross Margin (2021-2026)
13.13.4 Eugia Pharma Main Business Overview
13.13.5 Eugia Pharma Latest Developments
13.14 Lupin
13.14.1 Lupin Company Information
13.14.2 Lupin NK-1 Receptor Antagonists Product Portfolios and Specifications
13.14.3 Lupin NK-1 Receptor Antagonists Sales, Revenue, Price and Gross Margin (2021-2026)
13.14.4 Lupin Main Business Overview
13.14.5 Lupin Latest Developments
13.15 Dr. Reddy's Laboratories
13.15.1 Dr. Reddy's Laboratories Company Information
13.15.2 Dr. Reddy's Laboratories NK-1 Receptor Antagonists Product Portfolios and Specifications
13.15.3 Dr. Reddy's Laboratories NK-1 Receptor Antagonists Sales, Revenue, Price and Gross Margin (2021-2026)
13.15.4 Dr. Reddy's Laboratories Main Business Overview
13.15.5 Dr. Reddy's Laboratories Latest Developments
13.16 Chia Tai Tianqing Pharmaceutical
13.16.1 Chia Tai Tianqing Pharmaceutical Company Information
13.16.2 Chia Tai Tianqing Pharmaceutical NK-1 Receptor Antagonists Product Portfolios and Specifications
13.16.3 Chia Tai Tianqing Pharmaceutical NK-1 Receptor Antagonists Sales, Revenue, Price and Gross Margin (2021-2026)
13.16.4 Chia Tai Tianqing Pharmaceutical Main Business Overview
13.16.5 Chia Tai Tianqing Pharmaceutical Latest Developments
13.17 Qilu Pharmaceutical
13.17.1 Qilu Pharmaceutical Company Information
13.17.2 Qilu Pharmaceutical NK-1 Receptor Antagonists Product Portfolios and Specifications
13.17.3 Qilu Pharmaceutical NK-1 Receptor Antagonists Sales, Revenue, Price and Gross Margin (2021-2026)
13.17.4 Qilu Pharmaceutical Main Business Overview
13.17.5 Qilu Pharmaceutical Latest Developments
13.18 Beijing Sihuan Pharmaceutical
13.18.1 Beijing Sihuan Pharmaceutical Company Information
13.18.2 Beijing Sihuan Pharmaceutical NK-1 Receptor Antagonists Product Portfolios and Specifications
13.18.3 Beijing Sihuan Pharmaceutical NK-1 Receptor Antagonists Sales, Revenue, Price and Gross Margin (2021-2026)
13.18.4 Beijing Sihuan Pharmaceutical Main Business Overview
13.18.5 Beijing Sihuan Pharmaceutical Latest Developments
13.19 Yichang Humanwell Pharmaceutical
13.19.1 Yichang Humanwell Pharmaceutical Company Information
13.19.2 Yichang Humanwell Pharmaceutical NK-1 Receptor Antagonists Product Portfolios and Specifications
13.19.3 Yichang Humanwell Pharmaceutical NK-1 Receptor Antagonists Sales, Revenue, Price and Gross Margin (2021-2026)
13.19.4 Yichang Humanwell Pharmaceutical Main Business Overview
13.19.5 Yichang Humanwell Pharmaceutical Latest Developments
13.20 Hansoh Pharma
13.20.1 Hansoh Pharma Company Information
13.20.2 Hansoh Pharma NK-1 Receptor Antagonists Product Portfolios and Specifications
13.20.3 Hansoh Pharma NK-1 Receptor Antagonists Sales, Revenue, Price and Gross Margin (2021-2026)
13.20.4 Hansoh Pharma Main Business Overview
13.20.5 Hansoh Pharma Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. NK-1 Receptor Antagonists Annual Sales CAGR by Geographic Region (2021, 2025 & 2032) & ($ millions)
Table 2. NK-1 Receptor Antagonists Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of Aprepitant
Table 4. Major Players of Rolapitant
Table 5. Major Players of Fosaprepitant
Table 6. Major Players of Netupitant
Table 7. Major Players of Maropitant
Table 8. Major Players of Other
Table 9. Global NK-1 Receptor Antagonists Sales by Type (2021-2026) & (K Units)
Table 10. Global NK-1 Receptor Antagonists Sales Market Share by Type (2021-2026)
Table 11. Global NK-1 Receptor Antagonists Revenue by Type (2021-2026) & ($ million)
Table 12. Global NK-1 Receptor Antagonists Revenue Market Share by Type (2021-2026)
Table 13. Global NK-1 Receptor Antagonists Sale Price by Type (2021-2026) & (US$/Unit)
Table 14. Global NK-1 Receptor Antagonists Sale by Application (2021-2026) & (K Units)
Table 15. Global NK-1 Receptor Antagonists Sale Market Share by Application (2021-2026)
Table 16. Global NK-1 Receptor Antagonists Revenue by Application (2021-2026) & ($ million)
Table 17. Global NK-1 Receptor Antagonists Revenue Market Share by Application (2021-2026)
Table 18. Global NK-1 Receptor Antagonists Sale Price by Application (2021-2026) & (US$/Unit)
Table 19. Global NK-1 Receptor Antagonists Sales by Company (2021-2026) & (K Units)
Table 20. Global NK-1 Receptor Antagonists Sales Market Share by Company (2021-2026)
Table 21. Global NK-1 Receptor Antagonists Revenue by Company (2021-2026) & ($ millions)
Table 22. Global NK-1 Receptor Antagonists Revenue Market Share by Company (2021-2026)
Table 23. Global NK-1 Receptor Antagonists Sale Price by Company (2021-2026) & (US$/Unit)
Table 24. Key Manufacturers NK-1 Receptor Antagonists Producing Area Distribution and Sales Area
Table 25. Players NK-1 Receptor Antagonists Products Offered
Table 26. NK-1 Receptor Antagonists Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 27. New Products and Potential Entrants
Table 28. Market M&A Activity & Strategy
Table 29. Global NK-1 Receptor Antagonists Sales by Geographic Region (2021-2026) & (K Units)
Table 30. Global NK-1 Receptor Antagonists Sales Market Share Geographic Region (2021-2026)
Table 31. Global NK-1 Receptor Antagonists Revenue by Geographic Region (2021-2026) & ($ millions)
Table 32. Global NK-1 Receptor Antagonists Revenue Market Share by Geographic Region (2021-2026)
Table 33. Global NK-1 Receptor Antagonists Sales by Country/Region (2021-2026) & (K Units)
Table 34. Global NK-1 Receptor Antagonists Sales Market Share by Country/Region (2021-2026)
Table 35. Global NK-1 Receptor Antagonists Revenue by Country/Region (2021-2026) & ($ millions)
Table 36. Global NK-1 Receptor Antagonists Revenue Market Share by Country/Region (2021-2026)
Table 37. Americas NK-1 Receptor Antagonists Sales by Country (2021-2026) & (K Units)
Table 38. Americas NK-1 Receptor Antagonists Sales Market Share by Country (2021-2026)
Table 39. Americas NK-1 Receptor Antagonists Revenue by Country (2021-2026) & ($ millions)
Table 40. Americas NK-1 Receptor Antagonists Sales by Type (2021-2026) & (K Units)
Table 41. Americas NK-1 Receptor Antagonists Sales by Application (2021-2026) & (K Units)
Table 42. APAC NK-1 Receptor Antagonists Sales by Region (2021-2026) & (K Units)
Table 43. APAC NK-1 Receptor Antagonists Sales Market Share by Region (2021-2026)
Table 44. APAC NK-1 Receptor Antagonists Revenue by Region (2021-2026) & ($ millions)
Table 45. APAC NK-1 Receptor Antagonists Sales by Type (2021-2026) & (K Units)
Table 46. APAC NK-1 Receptor Antagonists Sales by Application (2021-2026) & (K Units)
Table 47. Europe NK-1 Receptor Antagonists Sales by Country (2021-2026) & (K Units)
Table 48. Europe NK-1 Receptor Antagonists Revenue by Country (2021-2026) & ($ millions)
Table 49. Europe NK-1 Receptor Antagonists Sales by Type (2021-2026) & (K Units)
Table 50. Europe NK-1 Receptor Antagonists Sales by Application (2021-2026) & (K Units)
Table 51. Middle East & Africa NK-1 Receptor Antagonists Sales by Country (2021-2026) & (K Units)
Table 52. Middle East & Africa NK-1 Receptor Antagonists Revenue Market Share by Country (2021-2026)
Table 53. Middle East & Africa NK-1 Receptor Antagonists Sales by Type (2021-2026) & (K Units)
Table 54. Middle East & Africa NK-1 Receptor Antagonists Sales by Application (2021-2026) & (K Units)
Table 55. Key Market Drivers & Growth Opportunities of NK-1 Receptor Antagonists
Table 56. Key Market Challenges & Risks of NK-1 Receptor Antagonists
Table 57. Key Industry Trends of NK-1 Receptor Antagonists
Table 58. NK-1 Receptor Antagonists Raw Material
Table 59. Key Suppliers of Raw Materials
Table 60. NK-1 Receptor Antagonists Distributors List
Table 61. NK-1 Receptor Antagonists Customer List
Table 62. Global NK-1 Receptor Antagonists Sales Forecast by Region (2027-2032) & (K Units)
Table 63. Global NK-1 Receptor Antagonists Revenue Forecast by Region (2027-2032) & ($ millions)
Table 64. Americas NK-1 Receptor Antagonists Sales Forecast by Country (2027-2032) & (K Units)
Table 65. Americas NK-1 Receptor Antagonists Annual Revenue Forecast by Country (2027-2032) & ($ millions)
Table 66. APAC NK-1 Receptor Antagonists Sales Forecast by Region (2027-2032) & (K Units)
Table 67. APAC NK-1 Receptor Antagonists Annual Revenue Forecast by Region (2027-2032) & ($ millions)
Table 68. Europe NK-1 Receptor Antagonists Sales Forecast by Country (2027-2032) & (K Units)
Table 69. Europe NK-1 Receptor Antagonists Revenue Forecast by Country (2027-2032) & ($ millions)
Table 70. Middle East & Africa NK-1 Receptor Antagonists Sales Forecast by Country (2027-2032) & (K Units)
Table 71. Middle East & Africa NK-1 Receptor Antagonists Revenue Forecast by Country (2027-2032) & ($ millions)
Table 72. Global NK-1 Receptor Antagonists Sales Forecast by Type (2027-2032) & (K Units)
Table 73. Global NK-1 Receptor Antagonists Revenue Forecast by Type (2027-2032) & ($ millions)
Table 74. Global NK-1 Receptor Antagonists Sales Forecast by Application (2027-2032) & (K Units)
Table 75. Global NK-1 Receptor Antagonists Revenue Forecast by Application (2027-2032) & ($ millions)
Table 76. Merck Basic Information, NK-1 Receptor Antagonists Manufacturing Base, Sales Area and Its Competitors
Table 77. Merck NK-1 Receptor Antagonists Product Portfolios and Specifications
Table 78. Merck NK-1 Receptor Antagonists Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 79. Merck Main Business
Table 80. Merck Latest Developments
Table 81. TerSera Therapeutics Basic Information, NK-1 Receptor Antagonists Manufacturing Base, Sales Area and Its Competitors
Table 82. TerSera Therapeutics NK-1 Receptor Antagonists Product Portfolios and Specifications
Table 83. TerSera Therapeutics NK-1 Receptor Antagonists Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 84. TerSera Therapeutics Main Business
Table 85. TerSera Therapeutics Latest Developments
Table 86. Helsinn Healthcare Basic Information, NK-1 Receptor Antagonists Manufacturing Base, Sales Area and Its Competitors
Table 87. Helsinn Healthcare NK-1 Receptor Antagonists Product Portfolios and Specifications
Table 88. Helsinn Healthcare NK-1 Receptor Antagonists Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 89. Helsinn Healthcare Main Business
Table 90. Helsinn Healthcare Latest Developments
Table 91. Heron Therapeutics Basic Information, NK-1 Receptor Antagonists Manufacturing Base, Sales Area and Its Competitors
Table 92. Heron Therapeutics NK-1 Receptor Antagonists Product Portfolios and Specifications
Table 93. Heron Therapeutics NK-1 Receptor Antagonists Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 94. Heron Therapeutics Main Business
Table 95. Heron Therapeutics Latest Developments
Table 96. Sandoz Basic Information, NK-1 Receptor Antagonists Manufacturing Base, Sales Area and Its Competitors
Table 97. Sandoz NK-1 Receptor Antagonists Product Portfolios and Specifications
Table 98. Sandoz NK-1 Receptor Antagonists Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 99. Sandoz Main Business
Table 100. Sandoz Latest Developments
Table 101. Glenmark Basic Information, NK-1 Receptor Antagonists Manufacturing Base, Sales Area and Its Competitors
Table 102. Glenmark NK-1 Receptor Antagonists Product Portfolios and Specifications
Table 103. Glenmark NK-1 Receptor Antagonists Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 104. Glenmark Main Business
Table 105. Glenmark Latest Developments
Table 106. Torrent Pharmaceuticals Basic Information, NK-1 Receptor Antagonists Manufacturing Base, Sales Area and Its Competitors
Table 107. Torrent Pharmaceuticals NK-1 Receptor Antagonists Product Portfolios and Specifications
Table 108. Torrent Pharmaceuticals NK-1 Receptor Antagonists Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 109. Torrent Pharmaceuticals Main Business
Table 110. Torrent Pharmaceuticals Latest Developments
Table 111. Steriscience Basic Information, NK-1 Receptor Antagonists Manufacturing Base, Sales Area and Its Competitors
Table 112. Steriscience NK-1 Receptor Antagonists Product Portfolios and Specifications
Table 113. Steriscience NK-1 Receptor Antagonists Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 114. Steriscience Main Business
Table 115. Steriscience Latest Developments
Table 116. Mylan Basic Information, NK-1 Receptor Antagonists Manufacturing Base, Sales Area and Its Competitors
Table 117. Mylan NK-1 Receptor Antagonists Product Portfolios and Specifications
Table 118. Mylan NK-1 Receptor Antagonists Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 119. Mylan Main Business
Table 120. Mylan Latest Developments
Table 121. Fresenius Basic Information, NK-1 Receptor Antagonists Manufacturing Base, Sales Area and Its Competitors
Table 122. Fresenius NK-1 Receptor Antagonists Product Portfolios and Specifications
Table 123. Fresenius NK-1 Receptor Antagonists Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 124. Fresenius Main Business
Table 125. Fresenius Latest Developments
Table 126. MSN Basic Information, NK-1 Receptor Antagonists Manufacturing Base, Sales Area and Its Competitors
Table 127. MSN NK-1 Receptor Antagonists Product Portfolios and Specifications
Table 128. MSN NK-1 Receptor Antagonists Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 129. MSN Main Business
Table 130. MSN Latest Developments
Table 131. Teva Basic Information, NK-1 Receptor Antagonists Manufacturing Base, Sales Area and Its Competitors
Table 132. Teva NK-1 Receptor Antagonists Product Portfolios and Specifications
Table 133. Teva NK-1 Receptor Antagonists Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 134. Teva Main Business
Table 135. Teva Latest Developments
Table 136. Eugia Pharma Basic Information, NK-1 Receptor Antagonists Manufacturing Base, Sales Area and Its Competitors
Table 137. Eugia Pharma NK-1 Receptor Antagonists Product Portfolios and Specifications
Table 138. Eugia Pharma NK-1 Receptor Antagonists Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 139. Eugia Pharma Main Business
Table 140. Eugia Pharma Latest Developments
Table 141. Lupin Basic Information, NK-1 Receptor Antagonists Manufacturing Base, Sales Area and Its Competitors
Table 142. Lupin NK-1 Receptor Antagonists Product Portfolios and Specifications
Table 143. Lupin NK-1 Receptor Antagonists Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 144. Lupin Main Business
Table 145. Lupin Latest Developments
Table 146. Dr. Reddy's Laboratories Basic Information, NK-1 Receptor Antagonists Manufacturing Base, Sales Area and Its Competitors
Table 147. Dr. Reddy's Laboratories NK-1 Receptor Antagonists Product Portfolios and Specifications
Table 148. Dr. Reddy's Laboratories NK-1 Receptor Antagonists Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 149. Dr. Reddy's Laboratories Main Business
Table 150. Dr. Reddy's Laboratories Latest Developments
Table 151. Chia Tai Tianqing Pharmaceutical Basic Information, NK-1 Receptor Antagonists Manufacturing Base, Sales Area and Its Competitors
Table 152. Chia Tai Tianqing Pharmaceutical NK-1 Receptor Antagonists Product Portfolios and Specifications
Table 153. Chia Tai Tianqing Pharmaceutical NK-1 Receptor Antagonists Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 154. Chia Tai Tianqing Pharmaceutical Main Business
Table 155. Chia Tai Tianqing Pharmaceutical Latest Developments
Table 156. Qilu Pharmaceutical Basic Information, NK-1 Receptor Antagonists Manufacturing Base, Sales Area and Its Competitors
Table 157. Qilu Pharmaceutical NK-1 Receptor Antagonists Product Portfolios and Specifications
Table 158. Qilu Pharmaceutical NK-1 Receptor Antagonists Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 159. Qilu Pharmaceutical Main Business
Table 160. Qilu Pharmaceutical Latest Developments
Table 161. Beijing Sihuan Pharmaceutical Basic Information, NK-1 Receptor Antagonists Manufacturing Base, Sales Area and Its Competitors
Table 162. Beijing Sihuan Pharmaceutical NK-1 Receptor Antagonists Product Portfolios and Specifications
Table 163. Beijing Sihuan Pharmaceutical NK-1 Receptor Antagonists Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 164. Beijing Sihuan Pharmaceutical Main Business
Table 165. Beijing Sihuan Pharmaceutical Latest Developments
Table 166. Yichang Humanwell Pharmaceutical Basic Information, NK-1 Receptor Antagonists Manufacturing Base, Sales Area and Its Competitors
Table 167. Yichang Humanwell Pharmaceutical NK-1 Receptor Antagonists Product Portfolios and Specifications
Table 168. Yichang Humanwell Pharmaceutical NK-1 Receptor Antagonists Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 169. Yichang Humanwell Pharmaceutical Main Business
Table 170. Yichang Humanwell Pharmaceutical Latest Developments
Table 171. Hansoh Pharma Basic Information, NK-1 Receptor Antagonists Manufacturing Base, Sales Area and Its Competitors
Table 172. Hansoh Pharma NK-1 Receptor Antagonists Product Portfolios and Specifications
Table 173. Hansoh Pharma NK-1 Receptor Antagonists Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 174. Hansoh Pharma Main Business
Table 175. Hansoh Pharma Latest Developments
Table 1. NK-1 Receptor Antagonists Annual Sales CAGR by Geographic Region (2021, 2025 & 2032) & ($ millions)
Table 2. NK-1 Receptor Antagonists Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of Aprepitant
Table 4. Major Players of Rolapitant
Table 5. Major Players of Fosaprepitant
Table 6. Major Players of Netupitant
Table 7. Major Players of Maropitant
Table 8. Major Players of Other
Table 9. Global NK-1 Receptor Antagonists Sales by Type (2021-2026) & (K Units)
Table 10. Global NK-1 Receptor Antagonists Sales Market Share by Type (2021-2026)
Table 11. Global NK-1 Receptor Antagonists Revenue by Type (2021-2026) & ($ million)
Table 12. Global NK-1 Receptor Antagonists Revenue Market Share by Type (2021-2026)
Table 13. Global NK-1 Receptor Antagonists Sale Price by Type (2021-2026) & (US$/Unit)
Table 14. Global NK-1 Receptor Antagonists Sale by Application (2021-2026) & (K Units)
Table 15. Global NK-1 Receptor Antagonists Sale Market Share by Application (2021-2026)
Table 16. Global NK-1 Receptor Antagonists Revenue by Application (2021-2026) & ($ million)
Table 17. Global NK-1 Receptor Antagonists Revenue Market Share by Application (2021-2026)
Table 18. Global NK-1 Receptor Antagonists Sale Price by Application (2021-2026) & (US$/Unit)
Table 19. Global NK-1 Receptor Antagonists Sales by Company (2021-2026) & (K Units)
Table 20. Global NK-1 Receptor Antagonists Sales Market Share by Company (2021-2026)
Table 21. Global NK-1 Receptor Antagonists Revenue by Company (2021-2026) & ($ millions)
Table 22. Global NK-1 Receptor Antagonists Revenue Market Share by Company (2021-2026)
Table 23. Global NK-1 Receptor Antagonists Sale Price by Company (2021-2026) & (US$/Unit)
Table 24. Key Manufacturers NK-1 Receptor Antagonists Producing Area Distribution and Sales Area
Table 25. Players NK-1 Receptor Antagonists Products Offered
Table 26. NK-1 Receptor Antagonists Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 27. New Products and Potential Entrants
Table 28. Market M&A Activity & Strategy
Table 29. Global NK-1 Receptor Antagonists Sales by Geographic Region (2021-2026) & (K Units)
Table 30. Global NK-1 Receptor Antagonists Sales Market Share Geographic Region (2021-2026)
Table 31. Global NK-1 Receptor Antagonists Revenue by Geographic Region (2021-2026) & ($ millions)
Table 32. Global NK-1 Receptor Antagonists Revenue Market Share by Geographic Region (2021-2026)
Table 33. Global NK-1 Receptor Antagonists Sales by Country/Region (2021-2026) & (K Units)
Table 34. Global NK-1 Receptor Antagonists Sales Market Share by Country/Region (2021-2026)
Table 35. Global NK-1 Receptor Antagonists Revenue by Country/Region (2021-2026) & ($ millions)
Table 36. Global NK-1 Receptor Antagonists Revenue Market Share by Country/Region (2021-2026)
Table 37. Americas NK-1 Receptor Antagonists Sales by Country (2021-2026) & (K Units)
Table 38. Americas NK-1 Receptor Antagonists Sales Market Share by Country (2021-2026)
Table 39. Americas NK-1 Receptor Antagonists Revenue by Country (2021-2026) & ($ millions)
Table 40. Americas NK-1 Receptor Antagonists Sales by Type (2021-2026) & (K Units)
Table 41. Americas NK-1 Receptor Antagonists Sales by Application (2021-2026) & (K Units)
Table 42. APAC NK-1 Receptor Antagonists Sales by Region (2021-2026) & (K Units)
Table 43. APAC NK-1 Receptor Antagonists Sales Market Share by Region (2021-2026)
Table 44. APAC NK-1 Receptor Antagonists Revenue by Region (2021-2026) & ($ millions)
Table 45. APAC NK-1 Receptor Antagonists Sales by Type (2021-2026) & (K Units)
Table 46. APAC NK-1 Receptor Antagonists Sales by Application (2021-2026) & (K Units)
Table 47. Europe NK-1 Receptor Antagonists Sales by Country (2021-2026) & (K Units)
Table 48. Europe NK-1 Receptor Antagonists Revenue by Country (2021-2026) & ($ millions)
Table 49. Europe NK-1 Receptor Antagonists Sales by Type (2021-2026) & (K Units)
Table 50. Europe NK-1 Receptor Antagonists Sales by Application (2021-2026) & (K Units)
Table 51. Middle East & Africa NK-1 Receptor Antagonists Sales by Country (2021-2026) & (K Units)
Table 52. Middle East & Africa NK-1 Receptor Antagonists Revenue Market Share by Country (2021-2026)
Table 53. Middle East & Africa NK-1 Receptor Antagonists Sales by Type (2021-2026) & (K Units)
Table 54. Middle East & Africa NK-1 Receptor Antagonists Sales by Application (2021-2026) & (K Units)
Table 55. Key Market Drivers & Growth Opportunities of NK-1 Receptor Antagonists
Table 56. Key Market Challenges & Risks of NK-1 Receptor Antagonists
Table 57. Key Industry Trends of NK-1 Receptor Antagonists
Table 58. NK-1 Receptor Antagonists Raw Material
Table 59. Key Suppliers of Raw Materials
Table 60. NK-1 Receptor Antagonists Distributors List
Table 61. NK-1 Receptor Antagonists Customer List
Table 62. Global NK-1 Receptor Antagonists Sales Forecast by Region (2027-2032) & (K Units)
Table 63. Global NK-1 Receptor Antagonists Revenue Forecast by Region (2027-2032) & ($ millions)
Table 64. Americas NK-1 Receptor Antagonists Sales Forecast by Country (2027-2032) & (K Units)
Table 65. Americas NK-1 Receptor Antagonists Annual Revenue Forecast by Country (2027-2032) & ($ millions)
Table 66. APAC NK-1 Receptor Antagonists Sales Forecast by Region (2027-2032) & (K Units)
Table 67. APAC NK-1 Receptor Antagonists Annual Revenue Forecast by Region (2027-2032) & ($ millions)
Table 68. Europe NK-1 Receptor Antagonists Sales Forecast by Country (2027-2032) & (K Units)
Table 69. Europe NK-1 Receptor Antagonists Revenue Forecast by Country (2027-2032) & ($ millions)
Table 70. Middle East & Africa NK-1 Receptor Antagonists Sales Forecast by Country (2027-2032) & (K Units)
Table 71. Middle East & Africa NK-1 Receptor Antagonists Revenue Forecast by Country (2027-2032) & ($ millions)
Table 72. Global NK-1 Receptor Antagonists Sales Forecast by Type (2027-2032) & (K Units)
Table 73. Global NK-1 Receptor Antagonists Revenue Forecast by Type (2027-2032) & ($ millions)
Table 74. Global NK-1 Receptor Antagonists Sales Forecast by Application (2027-2032) & (K Units)
Table 75. Global NK-1 Receptor Antagonists Revenue Forecast by Application (2027-2032) & ($ millions)
Table 76. Merck Basic Information, NK-1 Receptor Antagonists Manufacturing Base, Sales Area and Its Competitors
Table 77. Merck NK-1 Receptor Antagonists Product Portfolios and Specifications
Table 78. Merck NK-1 Receptor Antagonists Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 79. Merck Main Business
Table 80. Merck Latest Developments
Table 81. TerSera Therapeutics Basic Information, NK-1 Receptor Antagonists Manufacturing Base, Sales Area and Its Competitors
Table 82. TerSera Therapeutics NK-1 Receptor Antagonists Product Portfolios and Specifications
Table 83. TerSera Therapeutics NK-1 Receptor Antagonists Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 84. TerSera Therapeutics Main Business
Table 85. TerSera Therapeutics Latest Developments
Table 86. Helsinn Healthcare Basic Information, NK-1 Receptor Antagonists Manufacturing Base, Sales Area and Its Competitors
Table 87. Helsinn Healthcare NK-1 Receptor Antagonists Product Portfolios and Specifications
Table 88. Helsinn Healthcare NK-1 Receptor Antagonists Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 89. Helsinn Healthcare Main Business
Table 90. Helsinn Healthcare Latest Developments
Table 91. Heron Therapeutics Basic Information, NK-1 Receptor Antagonists Manufacturing Base, Sales Area and Its Competitors
Table 92. Heron Therapeutics NK-1 Receptor Antagonists Product Portfolios and Specifications
Table 93. Heron Therapeutics NK-1 Receptor Antagonists Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 94. Heron Therapeutics Main Business
Table 95. Heron Therapeutics Latest Developments
Table 96. Sandoz Basic Information, NK-1 Receptor Antagonists Manufacturing Base, Sales Area and Its Competitors
Table 97. Sandoz NK-1 Receptor Antagonists Product Portfolios and Specifications
Table 98. Sandoz NK-1 Receptor Antagonists Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 99. Sandoz Main Business
Table 100. Sandoz Latest Developments
Table 101. Glenmark Basic Information, NK-1 Receptor Antagonists Manufacturing Base, Sales Area and Its Competitors
Table 102. Glenmark NK-1 Receptor Antagonists Product Portfolios and Specifications
Table 103. Glenmark NK-1 Receptor Antagonists Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 104. Glenmark Main Business
Table 105. Glenmark Latest Developments
Table 106. Torrent Pharmaceuticals Basic Information, NK-1 Receptor Antagonists Manufacturing Base, Sales Area and Its Competitors
Table 107. Torrent Pharmaceuticals NK-1 Receptor Antagonists Product Portfolios and Specifications
Table 108. Torrent Pharmaceuticals NK-1 Receptor Antagonists Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 109. Torrent Pharmaceuticals Main Business
Table 110. Torrent Pharmaceuticals Latest Developments
Table 111. Steriscience Basic Information, NK-1 Receptor Antagonists Manufacturing Base, Sales Area and Its Competitors
Table 112. Steriscience NK-1 Receptor Antagonists Product Portfolios and Specifications
Table 113. Steriscience NK-1 Receptor Antagonists Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 114. Steriscience Main Business
Table 115. Steriscience Latest Developments
Table 116. Mylan Basic Information, NK-1 Receptor Antagonists Manufacturing Base, Sales Area and Its Competitors
Table 117. Mylan NK-1 Receptor Antagonists Product Portfolios and Specifications
Table 118. Mylan NK-1 Receptor Antagonists Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 119. Mylan Main Business
Table 120. Mylan Latest Developments
Table 121. Fresenius Basic Information, NK-1 Receptor Antagonists Manufacturing Base, Sales Area and Its Competitors
Table 122. Fresenius NK-1 Receptor Antagonists Product Portfolios and Specifications
Table 123. Fresenius NK-1 Receptor Antagonists Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 124. Fresenius Main Business
Table 125. Fresenius Latest Developments
Table 126. MSN Basic Information, NK-1 Receptor Antagonists Manufacturing Base, Sales Area and Its Competitors
Table 127. MSN NK-1 Receptor Antagonists Product Portfolios and Specifications
Table 128. MSN NK-1 Receptor Antagonists Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 129. MSN Main Business
Table 130. MSN Latest Developments
Table 131. Teva Basic Information, NK-1 Receptor Antagonists Manufacturing Base, Sales Area and Its Competitors
Table 132. Teva NK-1 Receptor Antagonists Product Portfolios and Specifications
Table 133. Teva NK-1 Receptor Antagonists Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 134. Teva Main Business
Table 135. Teva Latest Developments
Table 136. Eugia Pharma Basic Information, NK-1 Receptor Antagonists Manufacturing Base, Sales Area and Its Competitors
Table 137. Eugia Pharma NK-1 Receptor Antagonists Product Portfolios and Specifications
Table 138. Eugia Pharma NK-1 Receptor Antagonists Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 139. Eugia Pharma Main Business
Table 140. Eugia Pharma Latest Developments
Table 141. Lupin Basic Information, NK-1 Receptor Antagonists Manufacturing Base, Sales Area and Its Competitors
Table 142. Lupin NK-1 Receptor Antagonists Product Portfolios and Specifications
Table 143. Lupin NK-1 Receptor Antagonists Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 144. Lupin Main Business
Table 145. Lupin Latest Developments
Table 146. Dr. Reddy's Laboratories Basic Information, NK-1 Receptor Antagonists Manufacturing Base, Sales Area and Its Competitors
Table 147. Dr. Reddy's Laboratories NK-1 Receptor Antagonists Product Portfolios and Specifications
Table 148. Dr. Reddy's Laboratories NK-1 Receptor Antagonists Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 149. Dr. Reddy's Laboratories Main Business
Table 150. Dr. Reddy's Laboratories Latest Developments
Table 151. Chia Tai Tianqing Pharmaceutical Basic Information, NK-1 Receptor Antagonists Manufacturing Base, Sales Area and Its Competitors
Table 152. Chia Tai Tianqing Pharmaceutical NK-1 Receptor Antagonists Product Portfolios and Specifications
Table 153. Chia Tai Tianqing Pharmaceutical NK-1 Receptor Antagonists Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 154. Chia Tai Tianqing Pharmaceutical Main Business
Table 155. Chia Tai Tianqing Pharmaceutical Latest Developments
Table 156. Qilu Pharmaceutical Basic Information, NK-1 Receptor Antagonists Manufacturing Base, Sales Area and Its Competitors
Table 157. Qilu Pharmaceutical NK-1 Receptor Antagonists Product Portfolios and Specifications
Table 158. Qilu Pharmaceutical NK-1 Receptor Antagonists Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 159. Qilu Pharmaceutical Main Business
Table 160. Qilu Pharmaceutical Latest Developments
Table 161. Beijing Sihuan Pharmaceutical Basic Information, NK-1 Receptor Antagonists Manufacturing Base, Sales Area and Its Competitors
Table 162. Beijing Sihuan Pharmaceutical NK-1 Receptor Antagonists Product Portfolios and Specifications
Table 163. Beijing Sihuan Pharmaceutical NK-1 Receptor Antagonists Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 164. Beijing Sihuan Pharmaceutical Main Business
Table 165. Beijing Sihuan Pharmaceutical Latest Developments
Table 166. Yichang Humanwell Pharmaceutical Basic Information, NK-1 Receptor Antagonists Manufacturing Base, Sales Area and Its Competitors
Table 167. Yichang Humanwell Pharmaceutical NK-1 Receptor Antagonists Product Portfolios and Specifications
Table 168. Yichang Humanwell Pharmaceutical NK-1 Receptor Antagonists Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 169. Yichang Humanwell Pharmaceutical Main Business
Table 170. Yichang Humanwell Pharmaceutical Latest Developments
Table 171. Hansoh Pharma Basic Information, NK-1 Receptor Antagonists Manufacturing Base, Sales Area and Its Competitors
Table 172. Hansoh Pharma NK-1 Receptor Antagonists Product Portfolios and Specifications
Table 173. Hansoh Pharma NK-1 Receptor Antagonists Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 174. Hansoh Pharma Main Business
Table 175. Hansoh Pharma Latest Developments
LIST OF FIGURES
Figure 1. Picture of NK-1 Receptor Antagonists
Figure 2. NK-1 Receptor Antagonists Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global NK-1 Receptor Antagonists Sales Growth Rate 2021-2032 (K Units)
Figure 7. Global NK-1 Receptor Antagonists Revenue Growth Rate 2021-2032 ($ millions)
Figure 8. NK-1 Receptor Antagonists Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 9. NK-1 Receptor Antagonists Sales Market Share by Country/Region (2025)
Figure 10. NK-1 Receptor Antagonists Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 11. Product Picture of Aprepitant
Figure 12. Product Picture of Rolapitant
Figure 13. Product Picture of Fosaprepitant
Figure 14. Product Picture of Netupitant
Figure 15. Product Picture of Maropitant
Figure 16. Product Picture of Other
Figure 17. Global NK-1 Receptor Antagonists Sales Market Share by Type in 2026
Figure 18. Global NK-1 Receptor Antagonists Revenue Market Share by Type (2021-2026)
Figure 19. NK-1 Receptor Antagonists Consumed in Chemotherapy-induced Nausea and Vomiting (CINV)
Figure 20. Global NK-1 Receptor Antagonists Market: Chemotherapy-induced Nausea and Vomiting (CINV) (2021-2026) & (K Units)
Figure 21. NK-1 Receptor Antagonists Consumed in Postoperative Nausea and Vomiting (PONV)
Figure 22. Global NK-1 Receptor Antagonists Market: Postoperative Nausea and Vomiting (PONV) (2021-2026) & (K Units)
Figure 23. NK-1 Receptor Antagonists Consumed in Other
Figure 24. Global NK-1 Receptor Antagonists Market: Other (2021-2026) & (K Units)
Figure 25. Global NK-1 Receptor Antagonists Sale Market Share by Application (2025)
Figure 26. Global NK-1 Receptor Antagonists Revenue Market Share by Application in 2026
Figure 27. NK-1 Receptor Antagonists Sales by Company in 2026 (K Units)
Figure 28. Global NK-1 Receptor Antagonists Sales Market Share by Company in 2026
Figure 29. NK-1 Receptor Antagonists Revenue by Company in 2026 ($ millions)
Figure 30. Global NK-1 Receptor Antagonists Revenue Market Share by Company in 2026
Figure 31. Global NK-1 Receptor Antagonists Sales Market Share by Geographic Region (2021-2026)
Figure 32. Global NK-1 Receptor Antagonists Revenue Market Share by Geographic Region in 2026
Figure 33. Americas NK-1 Receptor Antagonists Sales 2021-2026 (K Units)
Figure 34. Americas NK-1 Receptor Antagonists Revenue 2021-2026 ($ millions)
Figure 35. APAC NK-1 Receptor Antagonists Sales 2021-2026 (K Units)
Figure 36. APAC NK-1 Receptor Antagonists Revenue 2021-2026 ($ millions)
Figure 37. Europe NK-1 Receptor Antagonists Sales 2021-2026 (K Units)
Figure 38. Europe NK-1 Receptor Antagonists Revenue 2021-2026 ($ millions)
Figure 39. Middle East & Africa NK-1 Receptor Antagonists Sales 2021-2026 (K Units)
Figure 40. Middle East & Africa NK-1 Receptor Antagonists Revenue 2021-2026 ($ millions)
Figure 41. Americas NK-1 Receptor Antagonists Sales Market Share by Country in 2026
Figure 42. Americas NK-1 Receptor Antagonists Revenue Market Share by Country (2021-2026)
Figure 43. Americas NK-1 Receptor Antagonists Sales Market Share by Type (2021-2026)
Figure 44. Americas NK-1 Receptor Antagonists Sales Market Share by Application (2021-2026)
Figure 45. United States NK-1 Receptor Antagonists Revenue Growth 2021-2026 ($ millions)
Figure 46. Canada NK-1 Receptor Antagonists Revenue Growth 2021-2026 ($ millions)
Figure 47. Mexico NK-1 Receptor Antagonists Revenue Growth 2021-2026 ($ millions)
Figure 48. Brazil NK-1 Receptor Antagonists Revenue Growth 2021-2026 ($ millions)
Figure 49. APAC NK-1 Receptor Antagonists Sales Market Share by Region in 2026
Figure 50. APAC NK-1 Receptor Antagonists Revenue Market Share by Region (2021-2026)
Figure 51. APAC NK-1 Receptor Antagonists Sales Market Share by Type (2021-2026)
Figure 52. APAC NK-1 Receptor Antagonists Sales Market Share by Application (2021-2026)
Figure 53. China NK-1 Receptor Antagonists Revenue Growth 2021-2026 ($ millions)
Figure 54. Japan NK-1 Receptor Antagonists Revenue Growth 2021-2026 ($ millions)
Figure 55. South Korea NK-1 Receptor Antagonists Revenue Growth 2021-2026 ($ millions)
Figure 56. Southeast Asia NK-1 Receptor Antagonists Revenue Growth 2021-2026 ($ millions)
Figure 57. India NK-1 Receptor Antagonists Revenue Growth 2021-2026 ($ millions)
Figure 58. Australia NK-1 Receptor Antagonists Revenue Growth 2021-2026 ($ millions)
Figure 59. China Taiwan NK-1 Receptor Antagonists Revenue Growth 2021-2026 ($ millions)
Figure 60. Europe NK-1 Receptor Antagonists Sales Market Share by Country in 2026
Figure 61. Europe NK-1 Receptor Antagonists Revenue Market Share by Country (2021-2026)
Figure 62. Europe NK-1 Receptor Antagonists Sales Market Share by Type (2021-2026)
Figure 63. Europe NK-1 Receptor Antagonists Sales Market Share by Application (2021-2026)
Figure 64. Germany NK-1 Receptor Antagonists Revenue Growth 2021-2026 ($ millions)
Figure 65. France NK-1 Receptor Antagonists Revenue Growth 2021-2026 ($ millions)
Figure 66. UK NK-1 Receptor Antagonists Revenue Growth 2021-2026 ($ millions)
Figure 67. Italy NK-1 Receptor Antagonists Revenue Growth 2021-2026 ($ millions)
Figure 68. Russia NK-1 Receptor Antagonists Revenue Growth 2021-2026 ($ millions)
Figure 69. Middle East & Africa NK-1 Receptor Antagonists Sales Market Share by Country (2021-2026)
Figure 70. Middle East & Africa NK-1 Receptor Antagonists Sales Market Share by Type (2021-2026)
Figure 71. Middle East & Africa NK-1 Receptor Antagonists Sales Market Share by Application (2021-2026)
Figure 72. Egypt NK-1 Receptor Antagonists Revenue Growth 2021-2026 ($ millions)
Figure 73. South Africa NK-1 Receptor Antagonists Revenue Growth 2021-2026 ($ millions)
Figure 74. Israel NK-1 Receptor Antagonists Revenue Growth 2021-2026 ($ millions)
Figure 75. Turkey NK-1 Receptor Antagonists Revenue Growth 2021-2026 ($ millions)
Figure 76. GCC Countries NK-1 Receptor Antagonists Revenue Growth 2021-2026 ($ millions)
Figure 77. Manufacturing Cost Structure Analysis of NK-1 Receptor Antagonists in 2026
Figure 78. Manufacturing Process Analysis of NK-1 Receptor Antagonists
Figure 79. Industry Chain Structure of NK-1 Receptor Antagonists
Figure 80. Channels of Distribution
Figure 81. Global NK-1 Receptor Antagonists Sales Market Forecast by Region (2027-2032)
Figure 82. Global NK-1 Receptor Antagonists Revenue Market Share Forecast by Region (2027-2032)
Figure 83. Global NK-1 Receptor Antagonists Sales Market Share Forecast by Type (2027-2032)
Figure 84. Global NK-1 Receptor Antagonists Revenue Market Share Forecast by Type (2027-2032)
Figure 85. Global NK-1 Receptor Antagonists Sales Market Share Forecast by Application (2027-2032)
Figure 86. Global NK-1 Receptor Antagonists Revenue Market Share Forecast by Application (2027-2032)
Figure 1. Picture of NK-1 Receptor Antagonists
Figure 2. NK-1 Receptor Antagonists Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global NK-1 Receptor Antagonists Sales Growth Rate 2021-2032 (K Units)
Figure 7. Global NK-1 Receptor Antagonists Revenue Growth Rate 2021-2032 ($ millions)
Figure 8. NK-1 Receptor Antagonists Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 9. NK-1 Receptor Antagonists Sales Market Share by Country/Region (2025)
Figure 10. NK-1 Receptor Antagonists Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 11. Product Picture of Aprepitant
Figure 12. Product Picture of Rolapitant
Figure 13. Product Picture of Fosaprepitant
Figure 14. Product Picture of Netupitant
Figure 15. Product Picture of Maropitant
Figure 16. Product Picture of Other
Figure 17. Global NK-1 Receptor Antagonists Sales Market Share by Type in 2026
Figure 18. Global NK-1 Receptor Antagonists Revenue Market Share by Type (2021-2026)
Figure 19. NK-1 Receptor Antagonists Consumed in Chemotherapy-induced Nausea and Vomiting (CINV)
Figure 20. Global NK-1 Receptor Antagonists Market: Chemotherapy-induced Nausea and Vomiting (CINV) (2021-2026) & (K Units)
Figure 21. NK-1 Receptor Antagonists Consumed in Postoperative Nausea and Vomiting (PONV)
Figure 22. Global NK-1 Receptor Antagonists Market: Postoperative Nausea and Vomiting (PONV) (2021-2026) & (K Units)
Figure 23. NK-1 Receptor Antagonists Consumed in Other
Figure 24. Global NK-1 Receptor Antagonists Market: Other (2021-2026) & (K Units)
Figure 25. Global NK-1 Receptor Antagonists Sale Market Share by Application (2025)
Figure 26. Global NK-1 Receptor Antagonists Revenue Market Share by Application in 2026
Figure 27. NK-1 Receptor Antagonists Sales by Company in 2026 (K Units)
Figure 28. Global NK-1 Receptor Antagonists Sales Market Share by Company in 2026
Figure 29. NK-1 Receptor Antagonists Revenue by Company in 2026 ($ millions)
Figure 30. Global NK-1 Receptor Antagonists Revenue Market Share by Company in 2026
Figure 31. Global NK-1 Receptor Antagonists Sales Market Share by Geographic Region (2021-2026)
Figure 32. Global NK-1 Receptor Antagonists Revenue Market Share by Geographic Region in 2026
Figure 33. Americas NK-1 Receptor Antagonists Sales 2021-2026 (K Units)
Figure 34. Americas NK-1 Receptor Antagonists Revenue 2021-2026 ($ millions)
Figure 35. APAC NK-1 Receptor Antagonists Sales 2021-2026 (K Units)
Figure 36. APAC NK-1 Receptor Antagonists Revenue 2021-2026 ($ millions)
Figure 37. Europe NK-1 Receptor Antagonists Sales 2021-2026 (K Units)
Figure 38. Europe NK-1 Receptor Antagonists Revenue 2021-2026 ($ millions)
Figure 39. Middle East & Africa NK-1 Receptor Antagonists Sales 2021-2026 (K Units)
Figure 40. Middle East & Africa NK-1 Receptor Antagonists Revenue 2021-2026 ($ millions)
Figure 41. Americas NK-1 Receptor Antagonists Sales Market Share by Country in 2026
Figure 42. Americas NK-1 Receptor Antagonists Revenue Market Share by Country (2021-2026)
Figure 43. Americas NK-1 Receptor Antagonists Sales Market Share by Type (2021-2026)
Figure 44. Americas NK-1 Receptor Antagonists Sales Market Share by Application (2021-2026)
Figure 45. United States NK-1 Receptor Antagonists Revenue Growth 2021-2026 ($ millions)
Figure 46. Canada NK-1 Receptor Antagonists Revenue Growth 2021-2026 ($ millions)
Figure 47. Mexico NK-1 Receptor Antagonists Revenue Growth 2021-2026 ($ millions)
Figure 48. Brazil NK-1 Receptor Antagonists Revenue Growth 2021-2026 ($ millions)
Figure 49. APAC NK-1 Receptor Antagonists Sales Market Share by Region in 2026
Figure 50. APAC NK-1 Receptor Antagonists Revenue Market Share by Region (2021-2026)
Figure 51. APAC NK-1 Receptor Antagonists Sales Market Share by Type (2021-2026)
Figure 52. APAC NK-1 Receptor Antagonists Sales Market Share by Application (2021-2026)
Figure 53. China NK-1 Receptor Antagonists Revenue Growth 2021-2026 ($ millions)
Figure 54. Japan NK-1 Receptor Antagonists Revenue Growth 2021-2026 ($ millions)
Figure 55. South Korea NK-1 Receptor Antagonists Revenue Growth 2021-2026 ($ millions)
Figure 56. Southeast Asia NK-1 Receptor Antagonists Revenue Growth 2021-2026 ($ millions)
Figure 57. India NK-1 Receptor Antagonists Revenue Growth 2021-2026 ($ millions)
Figure 58. Australia NK-1 Receptor Antagonists Revenue Growth 2021-2026 ($ millions)
Figure 59. China Taiwan NK-1 Receptor Antagonists Revenue Growth 2021-2026 ($ millions)
Figure 60. Europe NK-1 Receptor Antagonists Sales Market Share by Country in 2026
Figure 61. Europe NK-1 Receptor Antagonists Revenue Market Share by Country (2021-2026)
Figure 62. Europe NK-1 Receptor Antagonists Sales Market Share by Type (2021-2026)
Figure 63. Europe NK-1 Receptor Antagonists Sales Market Share by Application (2021-2026)
Figure 64. Germany NK-1 Receptor Antagonists Revenue Growth 2021-2026 ($ millions)
Figure 65. France NK-1 Receptor Antagonists Revenue Growth 2021-2026 ($ millions)
Figure 66. UK NK-1 Receptor Antagonists Revenue Growth 2021-2026 ($ millions)
Figure 67. Italy NK-1 Receptor Antagonists Revenue Growth 2021-2026 ($ millions)
Figure 68. Russia NK-1 Receptor Antagonists Revenue Growth 2021-2026 ($ millions)
Figure 69. Middle East & Africa NK-1 Receptor Antagonists Sales Market Share by Country (2021-2026)
Figure 70. Middle East & Africa NK-1 Receptor Antagonists Sales Market Share by Type (2021-2026)
Figure 71. Middle East & Africa NK-1 Receptor Antagonists Sales Market Share by Application (2021-2026)
Figure 72. Egypt NK-1 Receptor Antagonists Revenue Growth 2021-2026 ($ millions)
Figure 73. South Africa NK-1 Receptor Antagonists Revenue Growth 2021-2026 ($ millions)
Figure 74. Israel NK-1 Receptor Antagonists Revenue Growth 2021-2026 ($ millions)
Figure 75. Turkey NK-1 Receptor Antagonists Revenue Growth 2021-2026 ($ millions)
Figure 76. GCC Countries NK-1 Receptor Antagonists Revenue Growth 2021-2026 ($ millions)
Figure 77. Manufacturing Cost Structure Analysis of NK-1 Receptor Antagonists in 2026
Figure 78. Manufacturing Process Analysis of NK-1 Receptor Antagonists
Figure 79. Industry Chain Structure of NK-1 Receptor Antagonists
Figure 80. Channels of Distribution
Figure 81. Global NK-1 Receptor Antagonists Sales Market Forecast by Region (2027-2032)
Figure 82. Global NK-1 Receptor Antagonists Revenue Market Share Forecast by Region (2027-2032)
Figure 83. Global NK-1 Receptor Antagonists Sales Market Share Forecast by Type (2027-2032)
Figure 84. Global NK-1 Receptor Antagonists Revenue Market Share Forecast by Type (2027-2032)
Figure 85. Global NK-1 Receptor Antagonists Sales Market Share Forecast by Application (2027-2032)
Figure 86. Global NK-1 Receptor Antagonists Revenue Market Share Forecast by Application (2027-2032)
